Report
Chris Kallos, CFA
EUR 147.86 For Business Accounts Only

Sirtex Remains On Track After Solid Result; SARAH Readout now Expected in 2017; No change to FVE

Sirtex reported fiscal 2016 net profit after tax, or NPAT, of AUD 53.6 million on revenue of AUD 232.5 million, up 17.3% and 16.9%, respectively, on the prior year on a constant currency basis, meeting our expectations. Dose sales increased by 16.4% and was within recent guidance due to strong demand in the Americas which grew dose sales by 19% year on year. This was driven by expansion of sales efforts leveraging favourable Sirflox trial results presented at a major U.S. oncology conference in ...
Underlying
Sirtex Medical Limited

Sirtex Medical is a global life-sciences company based in Australia. Co. is engaged in developing and delivering effective oncology treatments using novel small particle technology. Co.'s main product is a targeted radioactive treatment for liver cancer called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered to the liver via Selective Internal Radiation Therapy.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Chris Kallos, CFA

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch